NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] 2015 Course on PK and PD of Protein Therapeutics

From: Meibohm, Bernd <>
Date: Thu, 5 Feb 2015 18:16:04 +0000

[Bernd Meibohm]<>

Bernd Meibohm<>

Professor & Associate Dean at University of Tennessee Health Science Center

Dear colleagues and friends,

It is my pleasure to announce that our 5th Annual Introductory Pharmacometric Training Course on

‘Pharmacokinetics and Pharmacodynamics of Protein Therapeutics - Concepts and Hands-On Modeling and Simulation’

will be held at the facilities of the University of Tennessee Health Science Center in Memphis, TN, USA, on April 13-17, 2015.

The 5-day course continues on the successful concept used in previous year offerings. It will introduce participants to basic principles in the pharmacokinetic and pharmacodynamic evaluation of novel therapeutic proteins and will provide opportunities for hands-on PK and PK/PD modeling and simulation examples relevant to therapeutic proteins. Topics include target-mediated drug disposition, tissue and tumor penetration, interspecies scaling, first-in-human dose selection, immunogenicity, model-based drug development, special populations, biosimilars, and drug-drug interactions. The target audience comprises pharmaceutical scientists from industry, academia and regulatory agencies with basic knowledge in PK and PKPD that had only limited exposure to the challenges associated with developing therapeutic proteins and that would like to receive a comprehensive overview or refresher on the PK and PKPD of this class of compounds. Although the course includes hands-on exercises, participants do NOT need to have prior experience with any particular PKPD analysis software.

For more detailed information on the preliminary course program and faculty, as well as on the registration process, please visit<>

I hope you will join us in April in Memphis!

Received on Thu Feb 05 2015 - 13:16:04 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: